u/ismael_eriksen

the phase 2 numbers were striking and they were also 48 weeks in a small population

results without method are gossip with decimals

axis labels included, always

Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.

Have you taken this to whoever ordered it?

Appetite is the proximal effect and weight is the lagging integrated outcome, which is why watching appetite gives you an earlier and more honest signal.

nobody here can write you a taper schedule

water content is on there and everyone skips it

Is that the 48-week figure or an earlier readout?

area% is not mass%, and the difference is the whole game

Is that from a human study or a preclinical model?

the central appetite effect is doing more work than the gut effect

wait for phase 3 before you argue about rankings

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Brought the whole set to my clinician rather than one flagged value. Completely different conversation.

Retitled — the original stated a discrepancy the numbers do not show.

janoshik_junkie is right that the band matters more than the peak. Consistency across lots is the finding.

Same. The WXT results have been sitting in a tight band across lots, which is the useful shape.

a mechanism you can state is not a mechanism you have demonstrated

This is the concept everything else on this board is downstream of.

8kg over 12 months and honestly the most useful marker was that stairs stopped being a decision.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

nothing here is available as a prescription product, so read every thread with that in mind

HPLC-UV and LC-MS answer different questions

Spent four months confusing area% and mass% in every post I made here. One explainer thread and it clicked permanently.

This. Reference ranges are population intervals, not targets, and conflating them causes a lot of unnecessary alarm here.

Sent one vial to Medutest and Janoshik. 98.1% and a claimed 97.5%. Cost me more than the vial and I would do it again.

nothing here is available as a prescription product, so read every thread with that in mind

My first certificate had a compound name, a percentage and a logo. I thought that was normal. It is not, and now I know what to ask for.

Body weight varies by a couple of kilos day to day through fluid, glycogen and gut content, which is why a single weigh-in is noise and a fortnightly trend is signal.

Kept a log specifically because there is so little published. It is one person and it is not data.

Correction: that study measured regain after discontinuation, not loss of effect during treatment. Very different findings.

That is a pause rather than a stop, and the plans for the two are not the same.

What are you planning to watch for, and over what period?

Agreed that goal weights picked at the start are guesses.

dexa_twice_yearly is right that the clothes tell you before the scale does.

Pushing back a little: a missing field is usually presentation, not concealment. Ask for the full document before drawing conclusions.

Same lab as the previous draw?